HBM Holdings Limited (HKG:2142)

Market Cap	10.20B +46.6%
Revenue (ttm)	1.23B +314.6%
Net Income	710.88M +3,187.7%
EPS	0.86 +2,958.9%
Shares Out	867.68M
PE Ratio	13.72
Forward PE	21.43
Dividend	n/a
Ex-Dividend Date	n/a

Volume	660,000
Open	11.75
Previous Close	11.75
Day's Range	11.23 - 11.76
52-Week Range	7.52 - 17.98
Beta	1.40
Analysts	Buy
Price Target	19.93 (+76.84%)
Earnings Date	Aug 27, 2026

About HBM Holdings

HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor for tr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 210
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2142

Financial Performance

In 2025, HBM Holdings's revenue was $157.98 million, an increase of 314.63% compared to the previous year's $38.10 million. Earnings were $91.33 million, an increase of 3187.72%.

Financial numbers in USD